Delcath Presents New Data on HEPZATO KIT™ Efficacy in Metastatic Uveal Melanoma at ESMO 2024
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company specializing in liver-targeted cancer therapies, announced new subgroup analysis data from the FOCUS Phase 3 trial of HEPZATO KIT™ (melphalan/Hepatic Delivery…